> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Eton/Azurity NDA Approved for Eprontia
- URL: https://www.fdaweb.com/eton-azurity-nda-approved-for-eprontia/
- Published: 2021-11-08T12:00:00.000Z
- Updated: 2026-09-14T17:21:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150536

FDA has approved an Eton Pharmaceuticals and Azurity Pharmaceuticals NDA for Eprontia (topiramate) oral solution, 25mg/mL, indicated as a monotherapy for treating partial-onset or primary generalized tonic-clonic seizures in patients two years of age and older. It is also indicated as an adjunctive therapy for treating partial-onset seizures, primary generalized tonic-clonic seizures or seizures associated with Lennox-Gastaut syndrome in patients two years of age and older; and as a migraine preventive treatment in patients 12 years of age and older.